Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 4ZC23 | IM |
Inappropriate Route of Administration; This non-serious case was reported by a other health professional via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a 25-year-old male patient who received MMR (Priorix) (batch number 4ZC23, expiry date 01-SEP-2025) for prophylaxis. On 25-NOV-2024, the patient received Priorix (intramuscular). On 25-NOV-2024, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: Inappropriate Route of Administration). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 28-MAR-2025 The reporter reported that an intramuscular administration of Priorix vaccine to a patient, which led to subcutaneous injection formulation administered by other route. The patient demographics, vaccine detail and vaccination date were obtained during this call. No further information was provided from the Vaccine Coordinator´s end in this call. The reporter consented to follow up. The Vaccine Administration Facility is the same as Primary Reporter.